Abeona Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$232.2M
Lead Investor(s):Jefferies LLC

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Abeona Therapeutics's estimated annual revenue is currently $5.3M per year.(?)
  • Abeona Therapeutics received $92.0M in venture funding in October 2017.
  • Abeona Therapeutics's estimated revenue per employee is $65,122
  • Abeona Therapeutics's total funding is $232.2M.

Employee Data

  • Abeona Therapeutics has 82 Employees.(?)
  • Abeona Therapeutics grew their employee count by -5% last year.
  • Abeona Therapeutics currently has 1 job openings.

Abeona Therapeutics Inc.(NASDAQ: $ABEO)is a leading clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.